The Insulin Resistance drugs in development market research report provides comprehensive information on the therapeutics under development for Insulin Resistance, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Insulin Resistance. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Insulin Resistance by six companies/universities/institutes. The top development phase for Insulin Resistance is preclinical with four drugs in that stage. The Insulin Resistance pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Insulin Resistance pipeline products market are: OrsoBio, Liminal BioSciences and Glycomantra.
The key targets in the Insulin Resistance pipeline products market include O2 Radical, Free Fatty Acid Receptor 1, and Galectin 3.
The key mechanisms of action in the Insulin Resistance pipeline product include ADP Ribosyl Cyclase/Cyclic ADP Ribose Hydrolase 1 Inhibitor with one drug in Preclinical. The Insulin Resistance pipeline products include two routes of administration with the top ROA being Oral and three key molecule types in the Insulin Resistance pipeline products market including Small Molecule, and Synthetic Peptide.
Insulin Resistance overview
Insulin resistance (IR) is a condition in which the body’s cells become resistant to the effects of insulin. This occurs when insulin levels are sufficiently high over a prolonged period of time, causing the body’s own sensitivity to the hormone to be reduced. Symptoms include lethargy, hunger, difficulty concentrating, and high blood pressure. Predisposing factors include obesity and hypertension.
For a complete picture of Insulin Resistance’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
